Research Comparison
Sermorelin vs Tesamorelin
Sermorelin and Tesamorelin are often compared because both sit in growth-hormone axis research. Sermorelin acts on GHRH receptor (GHRHR) and is studied for pituitary GH-secretion research, while Tesamorelin acts on GHRH analog and is studied for visceral/hepatic fat research. Both are supplied as lyophilized powder for in-vitro laboratory research only — this page compares mechanism and research status, not dosing or human use.
Sermorelin
Growth-hormone axis
Tesamorelin
Growth-hormone axis
Frequently asked
- What is the difference between Sermorelin and Tesamorelin?
- The main difference is mechanism and research stage. Sermorelin targets GHRH receptor (GHRHR) (research-use-only (former geref diagnostic)) and is studied for pituitary GH-secretion research; Tesamorelin targets GHRH analog (approved formulations exist) and is studied for visceral/hepatic fat research. Both are research-use-only compounds, not for human or animal use.
- Are Sermorelin and Tesamorelin approved for human use?
- No. Renova Wellness supplies both strictly for in-vitro laboratory and scientific research use only. Research status differs — Sermorelin: research-use-only (former geref diagnostic); Tesamorelin: approved formulations exist — but neither is sold for human or animal consumption, and no medical, therapeutic, or dosing claims are made.
- How is purity verified for Sermorelin and Tesamorelin?
- Every lot of both compounds ships with its own per-batch Certificate of Analysis — identity by mass spectrometry, ≥98% purity by HPLC, and a unique lot number you can verify against the vial in your hand.
Related comparisons
Build a multi-compound set in the Stack Builder or run the reconstitution calculator.
Research references
Primary literature for Sermorelin and Tesamorelin. Provided for scientific context only — not medical or dosing guidance.
- Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation. J Acquir Immune Defic Syndr. 2010. PMID 20101189 →
- Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014. PMID 25038357 →
Research use only. This comparison covers mechanism, target, and research status. It is not medical, therapeutic, or dosing advice. Compounds sold by Renova Wellness™ are for in-vitro laboratory research and are not for human or animal consumption.